Ascletis Pharma Inc. (HKG:1672)

Ascletis Pharma Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	593.37	1,444	865.73	330.12	403.77	2,495
Short-Term Investments	1,653	434.32	1,079	1,948	2,070	2.59
Trading Asset Securities	24.9	26.1	7.37	24.83	11.2	5.2
Cash & Short-Term Investments	2,271	1,904	1,953	2,303	2,485	2,503
Cash Growth	26.13%	-2.49%	-15.23%	-7.30%	-0.74%	-7.84%
Accounts Receivable	-	0.22	0.15	5.43	23.87	53.61
Other Receivables	17.36	9.94	9.11	12.85	5.4	13.79
Receivables	17.36	10.16	9.26	18.28	29.27	67.39
Inventory	1.17	1.87	4.37	6.07	20.52	56.23
Prepaid Expenses	4.73	4.75	2.26	1.03	2.13	2.3
Other Current Assets	-	-	2.37	4.13	8.13	2.34
Total Current Assets	2,295	1,921	1,971	2,333	2,545	2,632
Property, Plant & Equipment	40.29	46.7	57.07	68.28	71.83	77.51
Long-Term Investments	106.69	88.1	84.39	63.02	22.02	41.86
Other Intangible Assets	9.38	10.29	12.12	26.32	16.56	78.21
Long-Term Deferred Charges	0.38	0.46	0.08	0.38	0.7	0.42
Other Long-Term Assets	0.18	0.26	0.13	0.26	1.22	0.41
Total Assets	2,452	2,067	2,125	2,491	2,657	2,830

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	14.62	1.34	0.03	0.65	3.14	1.05
Accrued Expenses	118.58	87.12	83.8	91.87	56.15	52.29
Current Portion of Leases	2.24	2.87	6.25	5.71	2.42	1.57
Current Unearned Revenue	1.59	1.59	1.98	1.59	1.97	1.59
Other Current Liabilities	40.61	34.67	61	40.86	44.52	34.47
Total Current Liabilities	177.64	127.59	153.05	140.68	108.19	90.97
Long-Term Leases	1.5	2.29	1.39	2.71	1.82	1.18
Long-Term Unearned Revenue	1.59	2.38	3.97	5.56	7.15	8.73
Total Liabilities	180.72	132.26	158.41	148.94	117.16	100.89

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.73	0.68	0.69	0.73	0.74	0.75
Additional Paid-In Capital	-	3,135	2,750	2,843	2,867	2,884
Retained Earnings	-	-1,835	-1,475	-1,174	-1,030	-714.85
Treasury Stock	-	-83.43	-56.7	-51.95	-	-18.71
Comprehensive Income & Other	2,270	716.99	747.55	724.56	702	578.32
Total Common Equity	2,271	1,934	1,966	2,342	2,540	2,729
Shareholders' Equity	2,271	1,934	1,966	2,342	2,540	2,729
Total Liabilities & Equity	2,452	2,067	2,125	2,491	2,657	2,830

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	3.74	5.16	7.63	8.42	4.24	2.75
Net Cash (Debt)	2,268	1,899	1,945	2,295	2,480	2,501
Net Cash Growth	26.22%	-2.37%	-15.25%	-7.48%	-0.80%	-7.89%
Net Cash Per Share	2.24	1.95	1.94	2.14	2.28	2.28
Filing Date Shares Outstanding	1,040	991.87	971.07	1,061	1,087	1,096
Total Common Shares Outstanding	1,040	991.87	971.07	1,061	1,087	1,096
Working Capital	2,117	1,793	1,818	2,192	2,437	2,541
Book Value Per Share	2.18	1.95	2.02	2.21	2.34	2.49
Tangible Book Value	2,262	1,924	1,954	2,316	2,523	2,651
Tangible Book Value Per Share	2.18	1.94	2.01	2.18	2.32	2.42
Machinery	-	128.21	127.38	126.13	121.54	115.33
Construction In Progress	-	-	-	-	-	0.03
Leasehold Improvements	-	2.87	2.87	2.87	2.87	2.87

Data Source: S&P Global Market Intelligence Last updated: Aug 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Sep 10, 2026

Data Sources Report a data error